Carterra

Carterra unveils industry’s first 48-channel HT-SPR platform for label-free biomolecular screening

Carterra Inc. has launched the Vega™ High-Throughput Surface Plasmon Resonance (HT-SPR) instrument, the first 48-channel SPR platform to reach the market. The system is designed to address a long-standing throughput bottleneck in label-free binding analysis, offering a 12-fold increase in throughput compared to the current market-leading system across small and large molecule discovery workflows.

agilent s540md slide scanner

Agilent launches S540MD slide scanner system for European pathology laboratories

Agilent Technologies has introduced the S540MD Slide Scanner System, a whole slide imaging (WSI) platform designed for high-throughput digital pathology workflows in clinical laboratories.

Biotech 2

Biotech Fluidics launches flat film in-line degasser for HPLC and process applications

Biotech Fluidics has introduced the DEGASi® Flat Film in-line degasser, a system that replaces conventional tubular membranes with specialised flat film technology to remove dissolved gases from liquid streams. The design is aimed at instrument developers, manufacturers, and clinical and research laboratories requiring reliable degassing across a broad range of solvents and flow conditions.

Vetter 1

Vetter earns platinum EcoVadis rating and secures SBTi validation for emission reduction targets

Vetter, the Ravensburg-based Contract Development and Manufacturing Organisation (CDMO), has reinforced its sustainability credentials with two significant recognitions: a Platinum rating from the internationally renowned EcoVadis sustainability ranking and official validation of its emission reduction targets by the Science Based Targets initiative (SBTi).

Orikine Bio Larry Edwards

Orikine Bio strengthens board with appointment of seasoned pharma executive as chairman

Orikine Bio, the Barcelona-based biotechnology company developing next-generation immunotherapies, has appointed Larry Edwards as Chairman of its Board of Directors, effective 1 January 2026.

Axol Liam Taylor CEO Axol Bioscience

Axol Bioscience secures funding and expands iPSC portfolio

Cambridge and Edinburgh-based Axol Bioscience Ltd. has secured $2.8 million (£2.1 million) in new financing and completed a strategic acquisition, marking a significant period of growth for one of the UK’s leading providers of induced pluripotent stem cell (iPSC)-derived technologies for drug discovery and disease research.

AdobeStock 522372045

Indero pioneers quantitative gene expression method for rapid topical drug evaluation

Indero, a contract research organisation (CRO) specialising in dermatology and rheumatology, has announced the completion of an internally funded study introducing a novel approach to early-phase evaluation of topical new chemical entities (NCEs). The method applies quantitative gene expression analysis to generate efficacy signals within days rather than the weeks or months typically required by […]

Azenta image

Azenta’s FluidX tubes reach orbit in microgravity life sciences mission

Azenta, Inc. has announced a strategic partner­ship with UK space biotech company Frontier Space to conduct scientific experiments in microgravity, marking a notable step in the application of clinical-grade sample management technologies beyond Earth.

AdobeStock 336473160

Fresenius Kabi and TQ Therapeutics strike deal to scale T-cell therapy manufacturing

Fresenius Kabi and TQ Therapeutics have entered into a strategic-development agreement aimed at improving the scalability and efficiency of cell and gene therapy (CGT) manufacturing. The agreement grants Fresenius Kabi an exclusive licence to develop, manufacture, and distribute products incorporating TQ Therapeutics’ proprietary cell selection technology.

kupandoJorn Aldag

Kupando strengthens board with seasoned biotech chair to drive innate immunity platform forward

Kupando, a German biopharmaceutical company focused on innate immune stimulation, has appointed Jörn Aldag as Chair of its Board of Directors, signalling a strategic push towards clinical-stage development of its lead TLR 4/7 agonist candidate, KUP101.